Skip to main
MDXG
MDXG logo

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc has shown strong revenue performance, reporting $98.6 million in revenue for the latest quarter, which represents a year-over-year growth of approximately 13%, driven by robust contributions from both its wound and surgical product portfolios. The company's wound portfolio experienced a 12% year-over-year increase, while the surgical segment saw a more pronounced growth of 15%, highlighting the overall strengthening of its surgical business. Additionally, the upward revision of the 2025 revenue estimate to $387.3 million underscores confidence in ongoing sales momentum and operational performance.

Bears say

MiMedx Group Inc experienced a decline in gross margin, decreasing from approximately 83% to 81% in 2Q25, primarily attributed to production variances and changes in product mix, which may signal potential operational inefficiencies. The company's long-term guidance suggests a target of low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin exceeding 20%, but these goals appear optimistic given the recent margin decline. Furthermore, the company's reliance on reimbursement rates from CMS poses a vulnerability, as any adverse changes could significantly impact its revenue and overall business performance.

MiMedx Group (MDXG) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 2 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.